This study is currently not recruiting participants.

The Widespread Recruitment Initiative (WRI) of the Parkinson's Progression Markers Initiative (PPMI)

Investigating Markers of Parkinson's Disease Progression

Not Recruiting
100 years or below
All
Phase N/A
1 Location

Brief description of study.

The overall objective of the PPMI study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies. We are establishing a new website for a Widespread Recruitment Initiative (WRI) for the PPMI study. The purpose of the Widespread Recruitment Initiative is to identify individuals at increased risk of carrying a LRRK2 or GBA mutation(s) who may be willing to participate in the next phase of the PPMI study.

Detailed description of study

The overall objective of the PPMI study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies. We are establishing a new website for a Widespread Recruitment Initiative (WRI) for the PPMI study. The purpose of the Widespread Recruitment Initiative is to identify individuals at increased risk of carrying a LRRK2 or GBA mutation(s) who may be willing to participate in the next phase of the PPMI study.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Parkinson's Disease
  • Age: 100 years or below
  • Gender: All

This study investigates Parkinson's Disease (PD) and aims to find markers that show how the disease progresses. These markers can be clinical, which means based on patient symptoms and history, imaging, which involves pictures of the brain, or biologic, which are related to the body's natural processes. The goal is to use these markers in future clinical trials for treatments that might change the course of the disease.

Participants will undergo various procedures to identify if they are at increased risk of carrying specific genetic mutations, such as LRRK2 or GBA, which are linked to Parkinson's Disease. These procedures may include clinical assessments, imaging tests, and genetic screenings.

  • Who can participate: Individuals aged 18 and older who may be at increased risk of carrying LRRK2 or GBA mutations are eligible to participate.
  • Study details: Participants will be involved in procedures like clinical assessments, imaging tests, and genetic screenings to identify risk factors for Parkinson's Disease.
Updated on 19 Feb 2024. Study ID: 1312879913

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team